Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Development and Multicenter Validation of an Explainable System for Neonatal ARDS-Compatible Phenotyping

2 listopada 2026 zaktualizowane przez: Guangzhou Women and Children's Medical Center

Development and Multicenter Validation of an Explainable System for Identifying Clinical Phenotypes Compatible With Neonatal Acute Respiratory Distress Syndrome

Neonatal acute respiratory distress syndrome (NARDS) can be difficult to identify consistently because relevant information is distributed across clinical notes, imaging reports, and respiratory support records. This study will develop and validate an explainable system that organizes routinely collected electronic health record information and identifies infants whose clinical findings are compatible with NARDS.

The study will involve three neonatal intensive care units in China. Historical records from the lead center will be used for system development. A later period at the lead center and independent records from the two collaborating centers will be used for temporal and geographic validation. After the system has been locked, newly eligible infants will be included in a prospective validation phase without changing their clinical care.

System results will be compared with an independent reference assessment by neonatal intensive care specialists. The specialists will classify each infant's first eligible respiratory event as a high-likelihood NARDS-compatible clinical phenotype, a non-compatible clinical phenotype, clinically uncertain, or insufficient information. The study will evaluate sensitivity, specificity, predictive values, review workload, and the ability to identify insufficient information. During prospective validation, system results will remain unavailable to treating clinicians. The system is being evaluated as a research screening and review tool; it is not intended to replace a full clinical diagnosis or to determine treatment.

Przegląd badań

Status

Jeszcze nie rekrutacja

Szczegółowy opis

Study design and objective This is a three-center observational cohort study combining retrospective system development and validation with prospective validation of a locked system. Its objective is to develop an explainable electronic health record-based system for identifying a NARDS-compatible clinical phenotype and prioritizing candidate records for specialist review.

Establishment of retrospective cohorts Historical NICU records dated January 1, 2018, through December 31, 2025, will provide the retrospective source population. Records from the lead center dated 2018-2022 will form the development cohort. Records from the lead center dated 2023-2025 will form an independent internal temporal validation cohort. Records from each collaborating center dated 2023-2025 will form two separate geographic external validation cohorts. The planned formal adjudication sample is approximately 1,600 candidate events for development and 800 candidate events in each of the three retrospective validation cohorts. Each infant's first eligible event will be used in the primary analysis.

Candidate screening and sampling Candidate records will be identified using prespecified evidence of respiratory support or escalation, bilateral or diffuse pulmonary imaging abnormalities, acute lung injury triggers, or relevant diagnostic expressions. Diagnostic codes will be used for screening and descriptive analyses.

System development and locking The system will extract traceable evidence from imaging reports and other permitted clinical records, including acute respiratory deterioration, acute lung injury triggers, pulmonary imaging abnormalities, and alternative explanations. It will assign high-priority review, routine review, or insufficient-information status and retain the supporting source and timestamp. The variable dictionary, text-processing rules, feature mappings, decision rules, thresholds, software version, and analysis plan will be locked before validation. No retraining, threshold selection, or center-specific tuning will use validation labels.

Reference standard Two qualified neonatal intensive care specialists will independently assess each evidence package using a prespecified adjudication manual. Disagreement will undergo independent arbitration and, when necessary, structured consensus. Adjudicators will be masked to system outputs, explanations, discharge diagnostic labels, and diagnostic codes. They will assign one of four categories: high-likelihood NARDS-compatible clinical phenotype, non-compatible clinical phenotype, clinically uncertain, or insufficient information. The high-likelihood phenotype requires an acute respiratory course, evidence of an acute lung injury trigger, bilateral or diffuse pulmonary parenchymal imaging abnormalities, and no single alternative explanation that fully accounts for the findings.

Prospective validation After retrospective temporal and geographic validation, the same locked system will be assessed in newly eligible infants at the participating centers. The proposed prospective phase will include consecutive eligible infants and will preserve the same index-event definition, evidence window, reference standard, and output categories. Results will be generated in silent mode and will not be displayed to treating clinicians or used to guide care. Independent adjudicators will remain masked to system outputs. Prospective sample size, center participation, recruitment dates, and consent arrangements will be finalized in the protocol and ethics documentation before this phase begins.

Performance analysis The primary measure will be sensitivity of high-priority review for the reference-standard high-likelihood phenotype in each independent validation cohort. Results will be presented separately for the lead-center temporal cohort, each external center, and the prospective phase, with center-specific prospective results when sample size permits. Ninety-five percent confidence intervals will accompany performance estimates. Sampling weights will be used when estimating performance in the historical candidate population. These categories will remain visible in study flow and sensitivity analyses. The primary analysis uses one event per infant.

Data governance Identifiable records, original free text, images, and identity linkage files will remain within each center's authorized environment. Locked code will preferentially be run locally at collaborating centers. Only approved aggregate results and the minimum permitted de-identified audit information will be transferred to the coordinating center. No research-specific treatment or additional biological sampling is planned.

Typ studiów

Obserwacyjny

Zapisy (Szacowany)

1600

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

Nie starszy niż 1 miesiąc (Dziecko)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Metoda próbkowania

Próbka bez prawdopodobieństwa

Badana populacja

Infants in NICU at 3 participating hospitals before 44 weeks' postmenstrual age whose records meet ≥1 prespecified screening criterion for possible acute pulmonary injury. Historical candidates are sampled from prespecified center/calendar strata. The prospective phase consecutively enrolls newly eligible infants after system locking and retrospective validation. Separately identified screen-negative infants are reviewed if included in the registered screening audit. TTN, RDS, PPHN, pneumonia, and pulmonary hemorrhage are not automatic exclusions by diagnosis alone. Independent adjudication determines whether an alternative condition fully explains findings. Missing key evidence yields an uncertain/insufficient-information assessment, not automatic exclusion or a negative disease label.

Opis

Inclusion Criteria:

  1. Receiving care in the NICU of a participating hospital before 44 weeks of postmenstrual age at the index event.
  2. Meeting at least one prespecified candidate screening criterion, including a relevant acute lung injury or NARDS/ARDS expression, respiratory support or support escalation, bilateral or diffuse pulmonary parenchymal abnormalities in an imaging report, or a prespecified acute lung injury trigger.
  3. Having records within the prespecified center and calendar-period cohort, or being newly eligible during the approved prospective validation period.
  4. Availability of an appropriate legal basis for use of the records, including parental or guardian consent or an ethics-approved waiver when applicable.

Exclusion Criteria:

  1. Structural lung or airway malformations, complex congenital heart disease, or clearly established cardiac dysfunction or fluid overload that fully explains the respiratory failure and imaging abnormalities.
  2. Short-term postoperative mechanical ventilation without evidence of acute pulmonary injury.
  3. Duplicate or unresolvable records that prevent reliable identification of the infant or index event.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Modele obserwacyjne: COHORT
  • Perspektywy czasowe: OTHER

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Sensitivity of high-priority review for the high-likelihood NARDS-compatible clinical phenotype
Ramy czasowe: One assessment per first eligible respiratory event, using records from 48 hours before to 48 hours after the first screening trigger (T0).

We will calculate the high-priority proportion among expert-adjudicated NARDS-compatible infants, excluding routine-review and insufficient-information outputs, and report performance with 95% CIs by cohort, with uncertain assessments reported separately.

One assessment per first eligible respiratory event, using records from 48 hours before to 48 hours after the first screening trigger (T0).

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Positive predictive value of high-priority review
Ramy czasowe: One assessment per first eligible respiratory event, using records from 48 hours before to 48 hours after T0.

Among high-priority infants with determinate reference, report adjudicated high-likelihood NARDS-compatible proportion and 95% CI by cohort. Enriched samples yield sampling-weighted candidate estimates if permitted. It is not NICU-wide incidence.

One assessment per first eligible respiratory event, using records from 48 hours before to 48 hours after T0.
Negative predictive value for the high-priority triage policy
Ramy czasowe: One assessment per first eligible respiratory event, using records from 48 hours before to 48 hours after T0.

Among determinate-reference non-high-priority infants, report non-compatible phenotype proportion and 95%CI by cohort; describe routine-review and insufficient-information outputs separately, to avoid concealment. Weight historical estimates if possible.

One assessment per first eligible respiratory event, using records from 48 hours before to 48 hours after T0.
Proportion of infants with a determinate reference-standard assessment
Ramy czasowe: At reference adjudication of the first eligible event, using the same records from 48 hours before to 48 hours after T0.

Assessed infants with high-likelihood NARDS-compatible or non-compatible phenotype divided by all assessed; uncertain and insufficient-information assessments reported separately with reasons and 95% CIs, not relabeled negative or removed from flow.

At reference adjudication of the first eligible event, using the same records from 48 hours before to 48 hours after T0.

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Śledczy

  • Krzesło do nauki: Liyuan Hu, Ph.D., Guangzhou Women and Children's Medical Center

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Szacowany)

10 listopada 2026

Zakończenie podstawowe (Szacowany)

1 grudnia 2028

Ukończenie studiów (Szacowany)

1 grudnia 2028

Daty rejestracji na studia

Pierwszy przesłany

2 listopada 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

2 listopada 2026

Pierwszy wysłany (Rzeczywisty)

6 listopada 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

6 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

2 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • 2026-419A01

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj